Document is current
Any future updates will be listed below
-
Authors
Español-Rego, Marta
Fernández-Martos, Carlos
Elez, Elena
Foguet, Carles
Pedrosa, Leire
Rodríguez, Nuria
Ruiz-Casado, Ana
Pineda, Estela
Cid, Joan
Cabezón, Raquel
Oliveres, Helena
Lozano, Miquel
Ginés, Angels
García-Criado, Angeles
Ayuso, Juan Ramon
Pagés, Mario
Cuatrecasas, Miriam
Torres, Ferràn
Thomson, Timothy
Cascante, Marta
Benítez-Ribas, Daniel
Maurel, Joan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03152565 at ClinicalTrials.govDocuments that mention this clinical trial
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
https://doi.org/10.1007/s00262-022-03283-5
-
Funding
Funding for this research was provided by:
Plan Nacional de I+D (PID2020-115051RB-I00)
Plan Nacional de I+D (PID-107139RB-C21)
Instituto de Salud Carlos III (PI17/00732)
Instituto de Salud Carlos III (PI13/01728)
Hospital Clinic de Barcelona (Premi Fi de Residència Emili Letang)
Catalan Agency for Management of University and Research Grants (2014-SGR-474)
Catalan Agency for Management of University and Research Grants (2017-SGR-1174)
Fundació la Marató de TV3 (201330.10)
Fundación Olga Torres (Modalitat A.2019/2020)
- License Information
-
More Information
Article History
Received: 18 July 2022
Accepted: 15 August 2022
First Online: 9 September 2022
Declarations
:
: The authors declare that they have no competing interests.
: All patients enrolled signed an informed consent document approved by the investigator’s Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
